Pediatric oncology research is witnessing significant enhancements through advanced genomic profiling and novel immunotherapeutic strategies. The Princess Máxima Center has implemented comprehensive whole genome sequencing for all pediatric cancer patients, enabling precise tumor classification and personalized treatment decisions. Separately, researchers at Karolinska Institutet and Lund University have identified a promising dual enzyme inhibition approach targeting neuroblastoma, encouraging cancer cell differentiation and reducing tumor progression. These developments illustrate the growing integration of genomic data and targeted immune modulation to improve survival and reduce treatment-related toxicity in childhood cancers.